Your browser is no longer supported. Please, upgrade your browser.
Purple Biotech Ltd.
Index- P/E- EPS (ttm)- Insider Own1.91% Shs Outstand17.51M Perf Week-12.84%
Market Cap72.49M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float- Perf Month1.72%
Income- PEG- EPS next Q- Inst Own14.49% Short Float- Perf Quarter-2.59%
Sales1.00M P/S72.49 EPS this Y- Inst Trans- Short Ratio0.39 Perf Half Y2.73%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-27.50%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.20 - 14.40 Perf YTD8.66%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-71.25% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low88.18% ATR0.50
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)38.79 Volatility9.65% 10.78%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.47 Prev Close4.10
ShortableYes LT Debt/Eq- EarningsMar 02 BMO Payout- Avg Volume902.55K Price4.14
Recom- SMA20-22.96% SMA50-11.07% SMA200-21.40% Volume431,957 Change0.98%
Mar-03-21 07:00AM  
Mar-02-21 07:00AM  
Jan-18-21 07:41AM  
Jan-04-21 09:40AM  
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel.